Loading…
Employees: 1,418
Size DocMorris (DOCM.SW) is a Switzerland Health Care company (Medical Distributors) with a market value of $1.02B, the 120th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 16.50 on 6 Nov 2026.
Performance Over six months the shares gained 136.4%, against -6.8% for the median peer and +11.6% for the Switzerland market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 10.6% over the last twelve months (peer median +3.3%); the operating margin is -7.5% (peer median 1.8%).
Valuation It trades at 0.9× enterprise value to sales against a peer median of 0.6× (8th most expensive of 21).
Capital Return on invested capital runs 19.1 points below its cost of capital (6.5% WACC).
Credit DocMorris has 1 bond outstanding ($244M).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | CHF 1.12B | CHF 1.02B | CHF 969M | CHF 931M |
| Revenue growth | — | +11% | +5% | +4% | — |
| Gross profit | n/a | CHF 106M | CHF 71.1M | CHF 51.1M | CHF 6.85M |
| EBITDA | n/a | -CHF 39.4M | -CHF 45.9M | -CHF 32.4M | -CHF 98.9M |
| Net income | n/a | -CHF 134M | -CHF 97.3M | -CHF 114M | -CHF 170M |
| Free cash flow | n/a | -CHF 90.0M | -CHF 27.8M | -CHF 92.3M | -CHF 110M |
| Capital expenditure | n/a | CHF 27.3M | CHF 28.6M | CHF 27.7M | CHF 46.6M |
| Total debt | n/a | CHF 289M | CHF 312M | CHF 331M | CHF 529M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DOCM.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +20.7% | +0.8% | 2nd highest of 21 |
| 6-month return | +136.4% | -6.8% | highest of 21 |
| Distance from 52-week high | -3.1% | -20.3% | 3rd highest of 21 |
| Revenue growth (TTM) | +10.6% | +3.3% | 3rd highest of 21 |
| Operating margin | -7.5% | 1.8% | 2nd lowest of 21 |
| EV / Sales | 0.9× | 0.6× | 8th most expensive of 21 |
| ROIC minus cost of capital | -19.1 pp | +0.6 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | 0.9× | n/a | n/a |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 1.3× | -1.3% | +3.9% |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | 0.3× | n/a | n/a |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 0.4× | -9.5% | +6.0% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 1.3× | -1.0% | +6.3% |
| Shanghai Haohai Biological Technology 688366.SS | China | $946M | -24% | -9% | -2% | 2.0× | 18.9% | +13.2% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 0.7× | -5.9% | +1.2% |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 1.2× | 21.8% | +29.9% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | 0.6× | -1.3% | +17.9% |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 0.3× | 5.0% | +8.1% |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 0.2× | -14.7% | +7.6% |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 0.1× | -7.4% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | 0.5× | n/a | n/a |
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | 2.4× | 0.3% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | 0.8× | 14.4% | +7.5% |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 0.1× | -7.1% | +3.8% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | 1.2× | 12.2% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | 4.1× | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $475M | -60% | -22% | -1% | 0.6× | 59.0% | -7.8% |
| Suzuken 9987.T | Japan | $2.29B | -9% | +5% | 1% | 0.1× | -11.9% | +3.2% |
| Vital KSK 3151.T | Japan | $428M | +7% | +2% | 1% | 0.1× | 0.4% | +2.6% |
DocMorris has 1 bond outstanding with $244M face value.